FREE DELIVERY ON ALL ORDERS OVER £29*

*Conditions apply - details
Shop by Category
Please enable cookies to use this site. Why?

Free delivery on orders with a VetUK own brand product

Metacam

Metacam is a non-steroidal anti-inflammatory drug (NSAID) for use in cats and dogs. It can be used for alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats and dogs, e.g. orthopaedic and soft tissue surgery. Metacam oral suspension for cats is available in 15ml and Metacam oral suspension for dogs is available in 32ml, 100ml and 180ml bottle.

Metacam for Cats Oral Suspension 15ml

Metacam for Cats Oral Suspension 15ml

£10.15

Metacam Oral Suspension for CATS 15ml. Each ml contains 0.5 mg meloxicam as active ingredient (equivalent to 0.017 mg per drop) and 1.5 mg sodium benzoate (equivalent to 0.05 mg per drop)....[More info]

£10.15
Metacam for Dogs Oral Suspension

Metacam for Dogs Oral Suspension

From:£2.29to…£20.00

Metacam for Dogs oral suspension for dogs contains 1.5 mg meloxicam and 1.5 mg sodium benzoate per ml. Metacam for dog is a pleasantly flavoured liquid and can be added to food where most...[More info]

From:£2.29to…£20.00
Metacam Oral Suspension for Cats 30ml

Metacam Oral Suspension for Cats 30ml

£19.87

Metacam Oral Suspension for Cats 30ml is a non-steroidal anti-inflammatory drug (NSAID) for use in cats. It is used for the alleviation of inflammation and pain in chronic musculo-skeletal...[More info]

£19.87

Metacam is a non-steroidal anti-inflammatory drug (NSAID) for use in cats and dogs. For alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats and dogs, e.g. orthopaedic and soft tissue surgery. For alleviation of pain and inflammation in chronic musculo-skeletal disorders in cats and dogs.

Post-operative pain and inflammation following surgical procedures: After initial treatment with Metacam 2 mg/ml solution for injection for cats, continue treatment 24 hours later with Metacam 0.5 mg/ml oral suspension for cats at a dosage of 0.05 mg meloxicam/kg body weight. The oral follow-up dose may be administered once daily (at 24-hour intervals) for up to four days.

The suspension can be given using either the drop dispenser of the bottle (for very small breeds) or the Metacam measuring syringe provided in the package. Dosing procedure using the drop dispenser of the bottle.

Initial dose : 4 drops/kg bodyweight. Maintenance dose : 2 drops/kg bodyweight.

Chronic musculo-skeletal disorders: Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight.

A clinical response is normally seen within 7 days. Treatment should be discontinued after 14 days at the latest if no clinical improvement is apparent. Dosing procedure using the measuring syringe: The syringe fits onto the drop dispenser of the bottle and has a kg-body weight scale which corresponds to dose of 0.05 mg meloxicam/kg body weight. Thus for initiation of the treatment of chronic musculo-skeletal disorders on the first day, twice the maintenance volume will be required.

Shake well before use. To be administered orally either mixed with food or directly into the mouth.

The suspension can be given using the drop dispenser of the bottle for cats of any body weight. Alternatively and for cats with a body weight of at least 2 kg, the measuring syringe provided in the package can be used.

Particular care should be taken with regard to the accuracy of dosing. The recommended dose should not be exceeded. Avoid introduction of contamination during use. Do not use in pregnant or lactating animals.

Do not use in animals suffering from gastro-intestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients.Do not use in cats less than 6 weeks of age.

Typical adverse drug reactions of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported. These side effects are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.

If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity.

Post-operative pain and inflammation following surgical procedures: In case additional pain relief is required, multimodal pain therapy should be considered. Chronic musculoskeletal disorders: Response to long-term therapy should be monitored at regular intervals by a veterinary surgeon.

Other NSAIDs, diuretics, anticoagulant, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Metacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should be avoided.

Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the products used previously.

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels.

In case of overdose, adverse reactions, as listed in section 4.6, are expected to be more severe and more frequent. In case of overdose symptomatic treatment should be initiated.

People with known hypersensitivity to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. For animal treatment only. Keep out of reach of children.

Polyethylene bottles containing 3 ml or 15 ml with a polyethylene dropper, a tamper-proof child resistant closure and a polypropylene measuring syringe. The 1 ml measuring syringe has a kg-bodyweight scale for cats (2 to 10 kg) and has a pictogram showing a cat.

Meloxicam is a Non-Steroidal Anti-Inflammatory Drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

If the animal is fasted when dosed, the maximal plasma concentrations are obtained after approximately 3 hours. If the animal is fed at the time of dosing, the absorption may be slightly delayed.

There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97 % of meloxicam is bound to plasma proteins.

Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Five major metabolites have been identified. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. As for other species investigated, the main pathway of meloxicam biotransformation in cat is oxidation and there are no pharmacologically active metabolites.

Meloxicam is eliminated with a half-life of 24 hours. The detection of metabolites from the parent compound in urine and faeces, but not in plasma is indicative for their rapid excretion. 21% of the recovered dose is eliminated in urine (2% as unchanged meloxicam, 19% as metabolites) and 79% in the faeces (49% as unchanged meloxicam, 30% as metabolites).